{'fraction_non_alphanumeric': 0.01833180568285976, 'fraction_numerical': 0.006416131989000917, 'mean_word_length': 5.7407407407407405, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis

Giant cell arteritis (GCA) is associated with cranial ischaemic complications (CIC) including vision loss and stroke.1 British Society of Rheumatology and European League against Rheumatism guidelines recommend platelet inhibition with aspirin for most patients with GCA; on the basis of two retrospective studies showing a reduction in CICs, these results were not replicated in two other retrospective studies.2 3 There are no data from prospective or randomised controlled trials to support aspirin use in GCA.4 The glycoprotein VI (GPVI) receptor is found exclusively on platelets and megakaryocytes.5 GPVI is proteolytically cleaved following platelet activation and is detectable in plasma as soluble GPVI (sGPVI).6 Elevated plasma sGPVI signifies platelet activation and an increased risk of cardiovascular events.7 We have recently demonstrated enhanced platelet reactivity as measured by sGPVI in gout and rheumatoid arthritis, …